Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.

doi:10.1007/s11060-026-05712-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.

Journal of neuro-oncology - 23 Jul 2026

Carriere Patrick P, Haisraely Ory, Aaroe Ashley, Ahmed Kayode, Lewis Ryan, Colson-Fearon Darien, Bolden McArthur, Swanson Todd A, Beckham Thomas H, Wang Chenyang, De Brian, Perni Subha, Tom Martin C, Li Jing, McGovern Susan, McAleer Mary F, Ghia Amol, Jiang Wen, Chung Caroline, Grosshans David, Ballester Leomar, Esquenazi Yoshua, Kamiya-Matsuoka Carlos, Yeboa Debra Nana

Abstract excerpt

PURPOSE: IDH-wt diffuse gliomas with histologic grade 2-3 features and distinct molecular characteristics are now classified as molecular glioblastoma, yet outcomes and optimal management remain incompletely defined in a contemporary cohort. METHODS: Adults with histologic grade 2-3 IDH-wt gliomas diagnosed from 1996 to 2019 were retrospectively identified. Overall survival (OS) and progression-free survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Prognosis

Share to Survival Rate

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 42489814
DOI: 10.1007/s11060-026-05712-2
PMCID: PMC13395831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.PMID 42489814Read ↗

Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.Semantic proximity Read ↗

Current Considerations in the Treatment of Grade 3 Gliomas.Semantic proximity Read ↗

Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.Semantic proximity Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).Semantic proximity Read ↗

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.Semantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic FactorsSemantic proximity Read ↗

IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.Semantic proximity Read ↗

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.